» Articles » PMID: 30235698

A New Pathogenic Mutation of the BRCA1 Gene in a Patient with Ovarian Cancer: A Case Report

Overview
Specialty General Medicine
Date 2018 Sep 22
PMID 30235698
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene and tumor susceptibility gene. Germ line BRCA1/2 mutations significantly increase the risk of breast cancer and other cancers in women.

Patient Concerns: A 48-year-old woman was diagnosed with breast cancer at the age of 42 and subsequently diagnosed with ovarian cancer at the age of 48. Her sister had a history of breast cancer and her mother died from ovarian cancer.

Diagnoses: The patient has a family history of tumors. BRCA1/2 mutations was proved in this family members.

Interventions: Sanger sequencing was used to evaluate the BRCA1/2 gene status of the patient and her sister to identify the genetic mutation sites.

Outcomes: They had the same genetic mutation, namely, the c.3487_3488insA (p.Thr1163AsnfsX2) mutation in the BRCA1 gene, which is a novel mutation.

Lessons: This novel mutation may be a new pathogenic mutation of the BRCA1 gene. Its relationship to breast and ovarian cancers needs to be further verified in more patient cases. Moreover, mutant protein functions in both cell and animal models are also needed.

References
1.
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso M, Gilbert F . Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016; 27(suppl 5):v103-v110. DOI: 10.1093/annonc/mdw327. View

2.
Bristow R, Duska L, Lambrou N, Fishman E, ONeill M, Trimble E . A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000; 89(7):1532-40. DOI: 10.1002/1097-0142(20001001)89:7<1532::aid-cncr17>3.0.co;2-a. View

3.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

4.
Berek J, Crum C, Friedlander M . Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012; 119 Suppl 2:S118-29. DOI: 10.1016/S0020-7292(12)60025-3. View

5.
Plon S, Eccles D, Easton D, Foulkes W, Genuardi M, Greenblatt M . Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008; 29(11):1282-91. PMC: 3075918. DOI: 10.1002/humu.20880. View